{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:41:35Z","timestamp":1789612895757,"version":"build-2803163510"},"reference-count":44,"publisher":"eLife Sciences Publications, Ltd","license":[{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004203","name":"Ontario Institute for Cancer Research","doi-asserted-by":"publisher","award":["Clinical Investigator Award, IA-039"],"award-info":[{"award-number":["Clinical Investigator Award, IA-039"]}],"id":[{"id":"10.13039\/501100004203","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004376","name":"Terry Fox Research Institute","doi-asserted-by":"publisher","award":["Immunotherapy NeTwork (iTNT) Program"],"award-info":[{"award-number":["Immunotherapy NeTwork (iTNT) Program"]}],"id":[{"id":"10.13039\/501100004376","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Princess Margaret Cancer Centre","award":["Innovation Accelerator Fund"],"award-info":[{"award-number":["Innovation Accelerator Fund"]}]},{"DOI":"10.13039\/100009812","name":"Princess Margaret Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004489","name":"Mitacs","doi-asserted-by":"publisher","award":["Intership"],"award-info":[{"award-number":["Intership"]}],"id":[{"id":"10.13039\/501100004489","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["Postdoctoral Fellowship for Overseas Researchers"],"award-info":[{"award-number":["Postdoctoral Fellowship for Overseas Researchers"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Province of Ontario"},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","award":["Postgraduate Scholarship"],"award-info":[{"award-number":["Postgraduate Scholarship"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Guglietti Fellowship"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>HLA-restricted T cell responses can induce antitumor effects in cancer patients. Previous human T cell research has largely focused on the few HLA alleles prevalent in a subset of ethnic groups. Here, using a panel of newly developed peptide-exchangeable peptide\/HLA multimers and artificial antigen-presenting cells for 25 different class I alleles and greater than 800 peptides, we systematically and comprehensively mapped shared antigenic epitopes recognized by tumor-infiltrating T lymphocytes (TILs) from eight melanoma patients for all their class I alleles. We were able to determine the specificity, on average, of 12.2% of the TILs recognizing a mean of 3.1 shared antigen-derived epitopes across HLA-A, B, and C. Furthermore, we isolated a number of cognate T cell receptor genes with tumor reactivity. Our novel strategy allows for a more complete examination of the immune response and development of novel cancer immunotherapy not limited by HLA allele prevalence or tumor mutation burden.<\/jats:p>","DOI":"10.7554\/elife.53244","type":"journal-article","created":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T20:06:22Z","timestamp":1587413182000},"source":"Crossref","is-referenced-by-count":24,"title":["Landscape mapping of shared antigenic epitopes and their cognate TCRs of tumor-infiltrating T lymphocytes in melanoma"],"prefix":"10.7554","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2613-5144","authenticated-orcid":true,"given":"Kenji","family":"Murata","sequence":"first","affiliation":[{"name":"Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munehide","family":"Nakatsugawa","sequence":"additional","affiliation":[{"name":"Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed A","family":"Rahman","sequence":"additional","affiliation":[{"name":"Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linh T","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas G","family":"Millar","sequence":"additional","affiliation":[{"name":"Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T","family":"Mulder","sequence":"additional","affiliation":[{"name":"Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada"},{"name":"Princess Margaret Cancer Centre, University Health Network, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Sugata","sequence":"additional","affiliation":[{"name":"Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Saijo","sequence":"additional","affiliation":[{"name":"Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Matsunaga","sequence":"additional","affiliation":[{"name":"Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kagoya","sequence":"additional","affiliation":[{"name":"Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingxi","family":"Guo","sequence":"additional","affiliation":[{"name":"Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Anczurowski","sequence":"additional","affiliation":[{"name":"Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Hsi","family":"Wang","sequence":"additional","affiliation":[{"name":"Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada"},{"name":"Department of Immunology, University of Toronto, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian D","family":"Burt","sequence":"additional","affiliation":[{"name":"Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalam","family":"Ly","sequence":"additional","affiliation":[{"name":"Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayoko","family":"Saso","sequence":"additional","affiliation":[{"name":"Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Easson","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, University Health Network, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P","family":"Goldstein","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, University Health Network, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Reedijk","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, University Health Network, Toronto, Canada"},{"name":"Department of Medical Biophysics, University of Toronto, Toronto, Canada"},{"name":"Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Ghazarian","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathobiology, University Health Network, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor J","family":"Pugh","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, University Health Network, Toronto, Canada"},{"name":"Department of Medical Biophysics, University of Toronto, Toronto, Canada"},{"name":"Ontario Institute for Cancer Research, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus O","family":"Butler","sequence":"additional","affiliation":[{"name":"Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada"},{"name":"Department of Immunology, University of Toronto, Toronto, Canada"},{"name":"Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada"},{"name":"Department of Medicine, University of Toronto, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tak W","family":"Mak","sequence":"additional","affiliation":[{"name":"Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada"},{"name":"Department of Immunology, University of Toronto, Toronto, Canada"},{"name":"Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela S","family":"Ohashi","sequence":"additional","affiliation":[{"name":"Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada"},{"name":"Department of Immunology, University of Toronto, Toronto, Canada"},{"name":"Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9070-4754","authenticated-orcid":true,"given":"Naoto","family":"Hirano","sequence":"additional","affiliation":[{"name":"Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada"},{"name":"Department of Immunology, University of Toronto, Toronto, Canada"},{"name":"Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada"},{"name":"Ontario Institute for Cancer Research, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4374","published-online":{"date-parts":[[2020,4,21]]},"reference":[{"key":"bib1","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1158\/0008-5472.CAN-11-2614","article-title":"Dissection of T-cell antigen specificity in human melanoma","volume":"72","author":"Andersen","year":"2012","journal-title":"Cancer Research"},{"key":"bib2","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1093\/bioinformatics\/btv639","article-title":"Gapped sequence alignment using artificial neural networks: application to the MHC class I system","volume":"32","author":"Andreatta","year":"2016","journal-title":"Bioinformatics"},{"key":"bib3","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1038\/nbt.3662","article-title":"Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes","volume":"34","author":"Bentzen","year":"2016","journal-title":"Nature Biotechnology"},{"key":"bib4","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s00262-017-1971-5","article-title":"Evolution of MHC-based technologies used for detection of antigen-responsive T cells","volume":"66","author":"Bentzen","year":"2017","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"bib5","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/imr.12129","article-title":"Human cell-based artificial antigen-presenting cells for Cancer immunotherapy","volume":"257","author":"Butler","year":"2014","journal-title":"Immunological Reviews"},{"key":"bib6","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.4049\/jimmunol.1000629","article-title":"Modification of MHC anchor residues generates heteroclitic peptides that alter TCR binding and T cell recognition","volume":"185","author":"Cole","year":"2010","journal-title":"The Journal of Immunology"},{"key":"bib7","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/nrc3670","article-title":"Tumour antigens recognized by T lymphocytes: at the core of Cancer immunotherapy","volume":"14","author":"Coulie","year":"2014","journal-title":"Nature Reviews Cancer"},{"key":"bib8","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.biotechadv.2018.11.010","article-title":"Tracking antigen specific T-cells: technological advancement and limitations","volume":"37","author":"Dey","year":"2019","journal-title":"Biotechnology Advances"},{"key":"bib9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/imm.12499","article-title":"More tricks with tetramers: a practical guide to staining T cells with peptide-MHC multimers","volume":"146","author":"Dolton","year":"2015","journal-title":"Immunology"},{"key":"bib10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05072-0","article-title":"Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors","volume":"9","author":"Duhen","year":"2018","journal-title":"Nature Communications"},{"key":"bib11","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1053\/j.seminoncol.2015.05.005","article-title":"Adoptive cell therapy--Tumor-Infiltrating lymphocytes, T-Cell receptors, and chimeric antigen receptors","volume":"42","author":"Feldman","year":"2015","journal-title":"Seminars in Oncology"},{"key":"bib12","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/nrc.2016.97","article-title":"Engineered T cells: the promise and challenges of Cancer immunotherapy","volume":"16","author":"Fesnak","year":"2016","journal-title":"Nature Reviews Cancer"},{"key":"bib13","doi-asserted-by":"publisher","first-page":"385","DOI":"10.4049\/jimmunol.1701302","article-title":"A believer\u2019s Overview of Cancer Immunosurveillance and Immunotherapy","volume":"200","author":"Finn","year":"2018","journal-title":"The Journal of Immunology"},{"key":"bib14","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nri.2017.140","article-title":"The dawn of vaccines for Cancer prevention","volume":"18","author":"Finn","year":"2018","journal-title":"Nature Reviews Immunology"},{"key":"bib15","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028829","article-title":"Is it possible to develop Cancer vaccines to neoantigens, what are the major challenges, and how can these be overcome? neoantigens: nothing new in spite of the name","volume":"10","author":"Finn","year":"2018","journal-title":"Cold Spring Harbor Perspectives in Biology"},{"key":"bib16","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.1182\/blood-2003-05-1524","article-title":"Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region","volume":"102","author":"Heemskerk","year":"2003","journal-title":"Blood"},{"key":"bib17","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1182\/blood-2005-05-2073","article-title":"Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity","volume":"107","author":"Hirano","year":"2006","journal-title":"Blood"},{"key":"bib18","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nri.2017.131","article-title":"Towards personalized, tumour-specific, therapeutic vaccines for Cancer","volume":"18","author":"Hu","year":"2018","journal-title":"Nature Reviews Immunology"},{"key":"bib19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04262-0","article-title":"DOT1L inhibition attenuates graft-versus-host disease by allogeneic T cells in adoptive immunotherapy models","volume":"9","author":"Kagoya","year":"2018","journal-title":"Nature Communications"},{"key":"bib20","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1016\/j.molonc.2015.10.006","article-title":"T-cell receptor gene therapy--ready to go viral?","volume":"9","author":"Karpanen","year":"2015","journal-title":"Molecular Oncology"},{"key":"bib21","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1084\/jem.180.1.347","article-title":"Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes","volume":"180","author":"Kawakami","year":"1994","journal-title":"The Journal of Experimental Medicine"},{"key":"bib22","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1038\/nm.2764","article-title":"Monoclonal TCR-redirected tumor cell killing","volume":"18","author":"Liddy","year":"2012","journal-title":"Nature Medicine"},{"key":"bib23","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1073\/pnas.050567397","article-title":"HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors","volume":"97","author":"Migueles","year":"2000","journal-title":"PNAS"},{"key":"bib24","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1126\/science.1129003","article-title":"Cancer regression in patients after transfer of genetically engineered lymphocytes","volume":"314","author":"Morgan","year":"2006","journal-title":"Science"},{"key":"bib25","doi-asserted-by":"publisher","DOI":"10.1038\/srep23821","article-title":"CD4(+) and CD8(+) TCR\u03b2 repertoires possess different potentials to generate extraordinarily high-avidity T cells","volume":"6","author":"Nakatsugawa","year":"2016","journal-title":"Scientific Reports"},{"key":"bib26","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nbt.2593","article-title":"Combinatorial tetramer staining and mass cytometry analysis facilitate T-cell epitope mapping and characterization","volume":"31","author":"Newell","year":"2013","journal-title":"Nature Biotechnology"},{"key":"bib27","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s00262-019-02307-x","article-title":"Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2","volume":"68","author":"Nguyen","year":"2019","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"bib28","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1158\/2326-6066.CIR-14-0222","article-title":"Optimization of T-cell reactivity by exploiting TCR chain centricity for the purpose of safe and effective antitumor TCR gene therapy","volume":"3","author":"Ochi","year":"2015","journal-title":"Cancer Immunology Research"},{"key":"bib29","doi-asserted-by":"publisher","first-page":"11400","DOI":"10.1073\/pnas.93.21.11400","article-title":"A stable human-derived packaging cell line for production of high titer retrovirus\/vesicular stomatitis virus G pseudotypes","volume":"93","author":"Ory","year":"1996","journal-title":"PNAS"},{"key":"bib30","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/nm.3910","article-title":"NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma","volume":"21","author":"Rapoport","year":"2015","journal-title":"Nature Medicine"},{"key":"bib31","doi-asserted-by":"publisher","DOI":"10.5493\/wjem.v5.i1.11","article-title":"Internal ribosome entry site-based vectors for combined gene therapy","volume":"5","author":"Renaud-Gabardos","year":"2015","journal-title":"World Journal of Experimental Medicine"},{"key":"bib32","doi-asserted-by":"crossref","first-page":"303","DOI":"10.4049\/jimmunol.159.1.303","article-title":"The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes","volume":"159","author":"Robbins","year":"1997","journal-title":"Journal of Immunology"},{"key":"bib33","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-14-2708","article-title":"A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response","volume":"21","author":"Robbins","year":"2015","journal-title":"Clinical Cancer Research"},{"key":"bib34","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1126\/science.aar7112","article-title":"Personalized vaccines for Cancer immunotherapy","volume":"359","author":"Sahin","year":"2018","journal-title":"Science"},{"key":"bib35","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41591-018-0266-5","article-title":"Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers","volume":"25","author":"Scheper","year":"2019","journal-title":"Nature Medicine"},{"key":"bib36","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ccell.2014.12.004","article-title":"Biomarkers in cancer immunotherapy","volume":"27","author":"Schumacher","year":"2015","journal-title":"Cancer Cell"},{"key":"bib37","doi-asserted-by":"publisher","first-page":"D1237","DOI":"10.1093\/nar\/gkx664","article-title":"The SysteMHC atlas project","volume":"46","author":"Shao","year":"2018","journal-title":"Nucleic Acids Research"},{"key":"bib38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00947","article-title":"NY-ESO-1 based immunotherapy of Cancer: current perspectives","volume":"9","author":"Thomas","year":"2018","journal-title":"Frontiers in Immunology"},{"key":"bib39","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/nm1360","article-title":"Design and use of conditional MHC class I ligands","volume":"12","author":"Toebes","year":"2006","journal-title":"Nature Medicine"},{"key":"bib40","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","article-title":"T-Cell transfer therapy targeting mutant KRAS in Cancer","volume":"375","author":"Tran","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"bib41","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/ni.3682","article-title":"'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations","volume":"18","author":"Tran","year":"2017","journal-title":"Nature Immunology"},{"key":"bib42","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1002\/eji.200636765","article-title":"Enhanced immunogenicity of CTL antigens through mutation of the CD8 binding MHC class I invariant region","volume":"37","author":"Wooldridge","year":"2007","journal-title":"European Journal of Immunology"},{"key":"bib43","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/bs.ai.2015.12.006","article-title":"Adoptive T-Cell therapy for Cancer","volume":"130","author":"Yang","year":"2016","journal-title":"Advances in Immunology"},{"key":"bib44","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1158\/1078-0432.CCR-13-0945","article-title":"CD137 accurately identifies and enriches for naturally occurring Tumor-Reactive T cells in tumor","volume":"20","author":"Ye","year":"2014","journal-title":"Clinical Cancer Research"}],"container-title":["eLife"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cdn.elifesciences.org\/articles\/53244\/elife-53244-v2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/cdn.elifesciences.org\/articles\/53244\/elife-53244-v2.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/elifesciences.org\/articles\/53244","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T21:00:33Z","timestamp":1697058033000},"score":1,"resource":{"primary":{"URL":"https:\/\/elifesciences.org\/articles\/53244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,21]]},"references-count":44,"alternative-id":["10.7554\/eLife.53244"],"URL":"https:\/\/doi.org\/10.7554\/elife.53244","archive":["CLOCKSS"],"relation":{"has-review":[{"id-type":"doi","id":"10.7554\/eLife.53244.sa1","asserted-by":"object"},{"id-type":"doi","id":"10.7554\/eLife.53244.sa2","asserted-by":"object"}]},"ISSN":["2050-084X"],"issn-type":[{"value":"2050-084X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,21]]},"article-number":"e53244"}}